

to-BBB REALIZES €4M INVESTMENT ROUND ADVANCING BRAIN CANCER PRODUCT INTO CLINIC AND BROADENING CNS PLATFORM

Leiden, the Netherlands, February 3rd, 2011 -- [to-BBB Holding BV](#), the Dutch brain drug delivery company, has realized a first close of its Series-B investment round at €4Million. The company welcomes the Dutch Healthcare Investors of Jonghoud International BV and the Boston Life Science fund of the Industrial Bank of Taiwan Management Corporation (IBTM). The existing investors Aescap Venture and Antea Participaties also contributed to the round, which will enable to-BBB to enter the clinic with its brain cancer lead product before the summer and to develop other potential CNS therapies that utilize the company's proprietary G-Technology® for brain drug delivery.

“We are very proud to have Jonghoud and IBTM on board as new investors and to have the continuous support of Aescap and Antea” said Willem van Weperen, CEO of to-BBB. “The pharmaceutical heritage of Jonghoud and the important link to Asia of IBTM will be tremendously beneficial for the development of to-BBB.”

Fred Oudshoorn, Managing Director and Founder of Jonghoud, remarks: “With our experience in the pharma and healthcare area, we are looking forward to support to-BBB’s ambitions to become a leading brain drug delivery company.” Dr. Peter Wu, Chairman of Boston Life Science Fund (IBTM) adds: “As a biotech fund based in Taiwan, we are pleased to become an investor in to-BBB. While the G-Technology originated from Taiwan, we are keen to see it becoming a breakthrough in the blood-brain barrier area with the competence and efforts of to-BBB’s team.”

With this new investment to-BBB will obtain important clinical validation for its G-Technology by performing a phase I/II study with its lead product 2B3-101. This product for multiple brain cancer types will initially be studied in patients with brain metastases of breast cancer. The study will start in Q2 2011 and is planned to treat 30 patients. Furthermore, the company will broaden the application of the G-Technology in several other CNS indications both internally and with partners. In the last year the company has signed 10 collaborations with pharma companies to explore to-BBB’s proprietary G-Technology for development of CNS therapies.

This Series-B round supplemented by additional non-dilutive (governmental) funding programs will support the company for two years to make these important value steps. Patrick Krol, Partner at Aescap Venture and Chairman of to-BBB concludes: “The financing round will enable to-BBB to prove the strength of the G-Technology in patients and allow the company to further increase its value in other CNS diseases such as Alzheimer’s Disease and MS.”

About to-BBB

to-BBB is a private biotechnology company focusing on enhanced drug delivery across the blood-brain barrier. The Company is developing novel treatments for devastating brain disorders, such as brain cancer, neurodegenerative diseases and lysosomal storage diseases, by combining existing drugs with the G-Technology, to-BBB's proprietary brain delivery platform. This technology combines the widely used drug delivery approach of pegylated liposomes with the endogenous tripeptide glutathione as targeting ligand in a novel and safe way. Together with several top tier pharma and biotech companies, to-BBB is investigating the versatility of the G-Technology for drugs that are unable to reach the brain within a tolerable therapeutic window. to-BBB is applying the G-Technology for the delivery of doxorubicin for the treatment of brain cancer as its internal lead product 2B3-101.

to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.

Contact

Willem van Weperen, MSc, MBA
Chief Executive Officer

Phone: +31 71 3322252
Mobile: +31 634 054812
E-mail: vanweperen@toBBB.com

to-BBB technologies BV
Niels Bohrweg 11, 2333 CA Leiden
BioScience Park Leiden
Bio Partner Center II
The Netherlands
www.toBBB.com

Pieter Gaillard, PhD
Chief Scientific Officer

Phone: +31 71 3322251
Mobile: +31 621 525000
E-mail: gaillard@toBBB.com

to-BBB technologies BV
Niels Bohrweg 11, 2333 CA Leiden
BioScience Park Leiden
Bio Partner Center II
The Netherlands
www.toBBB.com